Improvement of vagal tone by ACE inhibition: A mechanism of cardioprotection in patients with mild-to-moderate heart failure

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 2, 1996, Pages

  Osterziel, Karl Josef ^a   Dietz, Rainer ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Heart failure; Parasympathetic nervous system; Prognosis; Renin angiotensin system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART FAILURE; HEART INDEX; HEART PROTECTION; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM; SYMPATHETIC TONE; VAGUS TONE;

EID: 0029880434     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600002-00006     Document Type: Conference Paper

References (34)

1. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1994;23: 1410-20.
2. Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-9.
3. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877-83.
4. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-8.
5. Hirsch AT, Pinto YM, Schunkert H, Dzau V. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D-32D.
6. Lee MA, Böhm M, Paul M, Ganten D. Tissue renin-angiotensin systems: their role in cardiovascular disease. Circulation 1993;87:IV-7-13.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
10. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;326:1429-35.
11. Waagstein F, Bristow M, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
12. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure (CIBIS). Circulation 1994;90: 1765-73.
13. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation 1988;78:816-24.
14. La Rovere MT, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L. Scopolamine improves autonomie balance in advanced congestive heart failure. Circulation 1994;90: 838-43.
15. Ludbrook J, Mancia G, Ferrari A, Zanchetti A. The variable-pressure neck-chamber method for studying the carotid baroreflex in man. Clin Sci 1977;53:165-71.
16. Ebert TJ. Captopril potentiates chronotropic baroreflex responses to carotid stimuli in humans. Hypertension 1985;7: 602-6.
17. Da Prada M, Zürcher G. Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 1976;19: 1161-74.
18. Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes. Biochim Biophys Acta 1978;522:574-88.
19. Schuster VL, Seidin DW. Renal clearance. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Raven Press, 1985:365-96.
20. Hinkle LE, Thaler HT. Clinical classification of cardiac death. Circulation 1982;65:457-64.
21. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
22. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI5-16.
23. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of physiology - the cardiovascular system III. Baltimore: Waverly Press, 1983:755-813.
24. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:177-91.
25. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982;66:874-80.
26. Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.
27. Osterziel KJ, Dietz R, Schmid W, Mikulaschek K, Manthey J, Kübler W. ACE-inhibition improves vagal reactivity in patients with heart failure. Am Heart J 1990;120:1120-9.
28. Schwarz F, Mall G, Zebe H, et al. Determinants of suvival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation 1984;70:923-8.
29. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the Consensus Trial). Am J Cardiol 1990;66:40D-5D.
30. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
31. Joy MD, Lowe RD. Evidence that the area postrema mediates the central cardiovascular response to angiotensin II. Nature 1970;228:1303-4.
32. Binkley PF, Haas GJ, Starling CR, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. Am J Cardiol 1993;21:655-61.
33. Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation 1993;87:VI49-55.
34. Goldman S, Johnson G, Cohn JN, Guillermo C, Smith R, Francis G. Mechanism of death in heart failure. Circulation 1993;87(suppl VI):VI-24-31.